Catalent Inc (NYSE:CTLT) Director Gregory T. Lucier bought 2,000 shares of Catalent stock in a transaction dated Thursday, February 13th. The shares were bought at an average cost of $60.45 per share, with a total value of $120,900.00.
Catalent stock opened at $60.45 on Friday. Catalent Inc has a twelve month low of $39.09 and a twelve month high of $68.78. The firm has a 50 day moving average price of $59.20 and a 200-day moving average price of $53.71. The company has a market capitalization of $8.73 billion, a P/E ratio of 71.96, a P/E/G ratio of 2.58 and a beta of 1.70. The company has a quick ratio of 1.60, a current ratio of 1.98 and a debt-to-equity ratio of 1.65.
Catalent (NYSE:CTLT) last released its earnings results on Monday, February 3rd. The company reported $0.45 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.39 by $0.06. Catalent had a net margin of 5.44% and a return on equity of 15.21%. The firm had revenue of $721.40 million during the quarter, compared to the consensus estimate of $700.81 million. During the same period in the prior year, the firm earned $0.45 EPS. The company’s revenue was up 15.8% compared to the same quarter last year. Equities analysts expect that Catalent Inc will post 1.78 EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in the company. Huntington National Bank purchased a new stake in shares of Catalent during the 4th quarter valued at approximately $32,000. Squar Milner Financial Services LLC lifted its stake in shares of Catalent by 173.4% during the 4th quarter. Squar Milner Financial Services LLC now owns 659 shares of the company’s stock valued at $37,000 after buying an additional 418 shares in the last quarter. Evoke Wealth LLC purchased a new stake in shares of Catalent during the 3rd quarter valued at approximately $42,000. Quest Capital Management Inc. ADV purchased a new stake in shares of Catalent during the 3rd quarter valued at approximately $53,000. Finally, Exchange Traded Concepts LLC purchased a new stake in shares of Catalent during the 4th quarter valued at approximately $90,000.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Article: Monthly Dividend Stocks Can Provide Solid Income
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.